Intriguingly, the FXR agonist Obeticholic acid has been shown to inhibit cell proliferation and invasion by repressing proliferative pathways in colon cancer cell lines and in a xenograft tumor model [50], and the synthetic FXR ligand GW4064 acts synergistically with the chemiotherapic agent oxaliplatin to inhibit colon cancer cells growth and their colony formation capabilities [51]. Here, NR1H4 is linked to colonic neoplasm.